RecruitingNCT06978322

Comparative Study Between Immediate Surgery Versus Neoadjuvant Chemotherapy for Management of Resectable Pancreatic Cancer

Sponsor

Minia University

Enrollment

30 participants

Start Date

Feb 1, 2025

Study Type

OBSERVATIONAL

Conditions

Surgery Neoadjuvant Chemotherapy Resectable Pancreatic Cancer Management

Summary

This trial aimed to determine whether neoadjuvant chemoradiotherapy improves overall survival compared with upfront surgery, both followed by adjuvant chemotherapy in patients with resectable and borderline resectable pancreatic cancer.

Eligibility

Min Age: 18 Years

Inclusion Criteria2

Computed tomography (CT) with pancreatic protocol + vascular mapping
Histopathologically proven malignant by CT-guided or endoscopic ultrasound (EUS)-guided biopsy Resectable pancreatic cancer means no contact of the tumor with the Superior mesenteric artery, Celiac axis \& Common hepatic artery, and contact of the tumor but ≤90° contact with the superior mesenteric vein \& portal vein.

Exclusion Criteria4

Borderline resectable \& locally advanced pancreatic cancer
Tumor at the tail of the pancreas.
Metastatic pancreatic cancer
Unfit patients for surgery.

Interventions

PROCEDUREImmediate surgery

Patients will undergo upfront surgery, then adjuvant chemotherapy.

PROCEDURENeoadjuvant chemotherapy

Patients will undergo neoadjuvant chemotherapy, then surgery.

Locations(1)

Minia University

Minya, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06978322

Related Trials

Effect of Virtual Reality on the Need of Premedication Before Surgery

NCT074504561 location

Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study.

NCT074008091 location